Oculis develops late stage drug candidates for eye and optic nerve diseases, based in Zug, Switzerland. OCS reports earnings on Tue, Nov 3, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 18 | HC Wainwright & Co. | Target raised | Buy | |
| Aug 14 | JP Morgan | Target lowered | Buy | |
| Aug 5 | HC Wainwright & Co. | Maintained | Buy | |
| Jun 3 | JP Morgan | Target lowered | Buy | |
| Jun 2 | Baird | Maintained | Buy |
Seasonality
How OCS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in OCS in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCS is in one of them and how their past OCS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered OCS in an article yet. Here's the latest on the wider market.
About Oculis Holding AG
Oculis is a biopharmaceutical company based in Zug, Switzerland, with operations in the U.S. and Iceland. It develops drug candidates for diseases of the eye and optic nerve. Its pipeline includes OCS-01, an eye drop being studied for diabetic macular edema, Licaminlimab, a topical treatment for dry eye disease, and Privosegtor, a neuroprotective candidate for optic neuritis and a related nerve condition. Its intended customers are patients and eye care doctors.
- Headquarters
- Zug, Switzerland